Hikma Pharmaceuticals logo

HIK - Hikma Pharmaceuticals Share Price

2540p -53.0  -2.0%

Last Trade - 15/01/21

Large Cap
Market Cap £5.85bn
Enterprise Value £6.22bn
Revenue £1.69bn
Position in Universe 157th / 1800
Unlock HIK Revenue
Relative Strength (%)
1m -1.35%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -8.24%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
1,489 1,440 1,950 1,936 2,076 2,203 2,315 2,505 +8.1%
+6.1 -7.2 +0.3 -31.9 +92.1 +18.4 -24.7 +12.6
Balance Sheet
FINANCIAL BRIEF: : For the six months ended 30 June 2020, HikmaPharmaceuticals Plc revenues increased 9% to $1.13B. Netincome increased 15% to $212M. Revenues reflect InjectablePharmaceuticals segment increase of 12% to $485M, BrandedPharmaceuticals segment increase of 14% to $275M, MiddleEast and North Africa segment increase of 17% to $351M,United States segment increase of 4% to $716M.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for HIK
Graphical History


HIK Revenue Unlock HIK Revenue

Net Income

HIK Net Income Unlock HIK Revenue

Normalised EPS

HIK Normalised EPS Unlock HIK Revenue

PE Ratio Range

HIK PE Ratio Range Unlock HIK Revenue

Dividend Yield Range

HIK Dividend Yield Range Unlock HIK Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
HIK EPS Forecasts Unlock HIK Revenue
Profile Summary

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company's segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets. The Company sells specialized generic injectable products across the globe. It also sells non-injectable generic products in the United States, supplying over 300 products in different dosage strengths and forms. The Company's other businesses comprise Arab Medical Containers, a manufacturer of plastic specialized medicinal sterile containers, International Pharmaceuticals Research Centre, which conducts bio-equivalency studies, and the active pharmaceutical ingredient (API) manufacturing division of Hikma Pharmaceuticals Limited Jordan.

Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated September 8, 2005
Public Since November 1, 2005
No. of Shareholders: n/a
No. of Employees: 8,578
HIK Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for HIK
Upcoming Events for HIK
Thursday 25th February, 2021 Estimate
Full Year 2020 Hikma Pharmaceuticals PLC Earnings Release
Frequently Asked Questions for Hikma Pharmaceuticals
What is the Hikma Pharmaceuticals share price?

As of 15/01/21, shares in Hikma Pharmaceuticals are trading at 2540p, giving the company a market capitalisation of £5.85bn. This share price information is delayed by 15 minutes.

How has the Hikma Pharmaceuticals share price performed this year?

Shares in Hikma Pharmaceuticals are currently trading at 2540p and the price has moved by 32.95% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Hikma Pharmaceuticals price has moved by 47.44% over the past year.

What are the analyst and broker recommendations for Hikma Pharmaceuticals?

Of the analysts with advisory recommendations for Hikma Pharmaceuticals, there are there are currently 4 "buy" , 2 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Hikma Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Hikma Pharmaceuticals next release its financial results?

Hikma Pharmaceuticals is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Hikma Pharmaceuticals dividend yield?

The Hikma Pharmaceuticals dividend yield is 1.39% based on the trailing twelve month period.

Does Hikma Pharmaceuticals pay a dividend?

Last year, Hikma Pharmaceuticals paid a total dividend of 0.48, and it currently has a trailing dividend yield of 1.39%. Looking ahead, Hikma Pharmaceuticals has not announced an ex-dividend date yet.

When does Hikma Pharmaceuticals next pay dividends?

Hikma Pharmaceuticals has yet to annouce their ex-dividend date. The historic dividend yield on Hikma Pharmaceuticals shares is currently 1.39%.

How do I buy Hikma Pharmaceuticals shares?

To buy shares in Hikma Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Hikma Pharmaceuticals?

Shares in Hikma Pharmaceuticals are currently trading at 2540p, giving the company a market capitalisation of £5.85bn.

Where are Hikma Pharmaceuticals shares listed? Where are Hikma Pharmaceuticals shares listed?

Here are the trading details for Hikma Pharmaceuticals:

Country of listing: United Kingdom
Exchange: LSE
Ticker Symbol: HIK
What kind of share is Hikma Pharmaceuticals?

Based on an overall assessment of its quality, value and momentum, Hikma Pharmaceuticals is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Hikma Pharmaceuticals share price forecast 2021?

Shares in Hikma Pharmaceuticals are currently priced at 2540p. At that level they are trading at 5.1% discount to the analyst consensus target price of 2,676.50.

Analysts covering Hikma Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of 1.697 for the next financial year.

How can I tell whether the Hikma Pharmaceuticals share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Hikma Pharmaceuticals. Over the past six months, the relative strength of its shares against the market has been 1.4%. At the current price of 2540p, shares in Hikma Pharmaceuticals are trading at 3.97% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Hikma Pharmaceuticals PE Ratio?

The Hikma Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is 14.79. The shares are currently trading at 2540p.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Hikma Pharmaceuticals?

Hikma Pharmaceuticals's management team is headed by:

Mazen Darwazah - VCH
Ali Al-Husry - NED
Bassam Wael Rushdi Kanaan - EVP
Majda Labadi - EVP
Susan Ringdal - EVP
Said Darwazah - CHM
Khalid Nabilsi - CFO
Riad Mishlawi - CEX
Patrick Butler - NID
John Castellani - NID
Nina Henderson - NID
Brian Hoffman - CEX
Sigurdur Olafsson - CEO
Henriette Nielsen - EVP
Douglas Hurt - NID
Who are the major shareholders of Hikma Pharmaceuticals?

Here are the top five shareholders of Hikma Pharmaceuticals based on the size of their shareholding:

Darhold Ltd Corporation
Percentage owned: 26.03% (60.0m shares)
Capital Research Global Investors Investment Advisor
Percentage owned: 10.1% (23.3m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 5.01% (11.5m shares)
Wellington Management Company, LLP Investment Advisor/Hedge Fund
Percentage owned: 5% (11.5m shares)
American Funds EuroPacific Growth Fund Mutual Fund
Percentage owned: 4.42% (10.2m shares)
Similar to HIK
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.